Effects of Carvedilol Versus Metoprolol on Endothelial Function and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

Alan J. Bank, Aaron S Kelly, Andrea M. Thelen, Daniel R. Kaiser, J. Michael Gonzalez-Campoy

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Data suggest that carvedilol possesses antioxidant properties that might provide vascular protection. We sought to compare the effects of carvedilol and metoprolol tartrate on endothelial function and oxidative stress in a head-to-head trial. Methods: Thirty-four patients with type 2 diabetes mellitus (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or metoprolol (n = 18) in addition to their current antihypertensive medications for 5 months. The following variables were measured pre- and posttreatment: blood pressure, fasting glucose and insulin, insulin resistance by homeostasis-model assessment, hemoglobin A1c, lipids, C-reactive protein (CRP), 8-isoprostane, asymmetric dimethylarginine, oxidized LDL cholesterol, ultrasound assessment of brachial-artery flow-mediated dilation (FMD), nitroglycerin-induced endothelium-independent dilation (EID), brachial and carotid artery distension, distensibility and compliance, and carotid artery intima-media thickness (cIMT). Results: Both carvedilol and metoprolol treatment resulted in significant and similar decreases in systolic (P < .05) and diastolic (P < .0001) blood pressure. Compared with metoprolol, carvedilol significantly improved FMD (P < .001). No differences between groups were noted for any of the glycemic or lipid variables except for HDL cholesterol, which significantly decreased (P < .05) in the metoprolol group compared with the carvedilol group. No differences were observed between groups for CRP, the markers of oxidative stress, EID, arterial stiffness, or cIMT. Conclusions: Compared with metoprolol, carvedilol significantly improves endothelial function in patients with T2DM. Changes in glycemic control and oxidative stress do not seem to explain the observed improvements in FMD, which suggests that other mechanisms may be involved.

Original languageEnglish (US)
Pages (from-to)777-783
Number of pages7
JournalAmerican journal of hypertension
Volume20
Issue number7
DOIs
StatePublished - Jul 1 2007

Fingerprint

Metoprolol
Type 2 Diabetes Mellitus
Oxidative Stress
Dilatation
Carotid Arteries
Carotid Intima-Media Thickness
8-epi-prostaglandin F2alpha
Brachial Artery
C-Reactive Protein
Endothelium
Blood Pressure
Lipids
Vascular Stiffness
Nitroglycerin
carvedilol
LDL Cholesterol
HDL Cholesterol
Antihypertensive Agents
Compliance
Blood Vessels

Keywords

  • endothelial function
  • oxidative stress
  • type 2 diabetes mellitus
  • β-blocker

Cite this

Effects of Carvedilol Versus Metoprolol on Endothelial Function and Oxidative Stress in Patients With Type 2 Diabetes Mellitus. / Bank, Alan J.; Kelly, Aaron S; Thelen, Andrea M.; Kaiser, Daniel R.; Gonzalez-Campoy, J. Michael.

In: American journal of hypertension, Vol. 20, No. 7, 01.07.2007, p. 777-783.

Research output: Contribution to journalArticle

Bank, Alan J. ; Kelly, Aaron S ; Thelen, Andrea M. ; Kaiser, Daniel R. ; Gonzalez-Campoy, J. Michael. / Effects of Carvedilol Versus Metoprolol on Endothelial Function and Oxidative Stress in Patients With Type 2 Diabetes Mellitus. In: American journal of hypertension. 2007 ; Vol. 20, No. 7. pp. 777-783.
@article{3d67936c3c7249bcb30a4f9864c8db9d,
title = "Effects of Carvedilol Versus Metoprolol on Endothelial Function and Oxidative Stress in Patients With Type 2 Diabetes Mellitus",
abstract = "Background: Data suggest that carvedilol possesses antioxidant properties that might provide vascular protection. We sought to compare the effects of carvedilol and metoprolol tartrate on endothelial function and oxidative stress in a head-to-head trial. Methods: Thirty-four patients with type 2 diabetes mellitus (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or metoprolol (n = 18) in addition to their current antihypertensive medications for 5 months. The following variables were measured pre- and posttreatment: blood pressure, fasting glucose and insulin, insulin resistance by homeostasis-model assessment, hemoglobin A1c, lipids, C-reactive protein (CRP), 8-isoprostane, asymmetric dimethylarginine, oxidized LDL cholesterol, ultrasound assessment of brachial-artery flow-mediated dilation (FMD), nitroglycerin-induced endothelium-independent dilation (EID), brachial and carotid artery distension, distensibility and compliance, and carotid artery intima-media thickness (cIMT). Results: Both carvedilol and metoprolol treatment resulted in significant and similar decreases in systolic (P < .05) and diastolic (P < .0001) blood pressure. Compared with metoprolol, carvedilol significantly improved FMD (P < .001). No differences between groups were noted for any of the glycemic or lipid variables except for HDL cholesterol, which significantly decreased (P < .05) in the metoprolol group compared with the carvedilol group. No differences were observed between groups for CRP, the markers of oxidative stress, EID, arterial stiffness, or cIMT. Conclusions: Compared with metoprolol, carvedilol significantly improves endothelial function in patients with T2DM. Changes in glycemic control and oxidative stress do not seem to explain the observed improvements in FMD, which suggests that other mechanisms may be involved.",
keywords = "endothelial function, oxidative stress, type 2 diabetes mellitus, β-blocker",
author = "Bank, {Alan J.} and Kelly, {Aaron S} and Thelen, {Andrea M.} and Kaiser, {Daniel R.} and Gonzalez-Campoy, {J. Michael}",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.amjhyper.2007.01.019",
language = "English (US)",
volume = "20",
pages = "777--783",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Effects of Carvedilol Versus Metoprolol on Endothelial Function and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

AU - Bank, Alan J.

AU - Kelly, Aaron S

AU - Thelen, Andrea M.

AU - Kaiser, Daniel R.

AU - Gonzalez-Campoy, J. Michael

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Background: Data suggest that carvedilol possesses antioxidant properties that might provide vascular protection. We sought to compare the effects of carvedilol and metoprolol tartrate on endothelial function and oxidative stress in a head-to-head trial. Methods: Thirty-four patients with type 2 diabetes mellitus (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or metoprolol (n = 18) in addition to their current antihypertensive medications for 5 months. The following variables were measured pre- and posttreatment: blood pressure, fasting glucose and insulin, insulin resistance by homeostasis-model assessment, hemoglobin A1c, lipids, C-reactive protein (CRP), 8-isoprostane, asymmetric dimethylarginine, oxidized LDL cholesterol, ultrasound assessment of brachial-artery flow-mediated dilation (FMD), nitroglycerin-induced endothelium-independent dilation (EID), brachial and carotid artery distension, distensibility and compliance, and carotid artery intima-media thickness (cIMT). Results: Both carvedilol and metoprolol treatment resulted in significant and similar decreases in systolic (P < .05) and diastolic (P < .0001) blood pressure. Compared with metoprolol, carvedilol significantly improved FMD (P < .001). No differences between groups were noted for any of the glycemic or lipid variables except for HDL cholesterol, which significantly decreased (P < .05) in the metoprolol group compared with the carvedilol group. No differences were observed between groups for CRP, the markers of oxidative stress, EID, arterial stiffness, or cIMT. Conclusions: Compared with metoprolol, carvedilol significantly improves endothelial function in patients with T2DM. Changes in glycemic control and oxidative stress do not seem to explain the observed improvements in FMD, which suggests that other mechanisms may be involved.

AB - Background: Data suggest that carvedilol possesses antioxidant properties that might provide vascular protection. We sought to compare the effects of carvedilol and metoprolol tartrate on endothelial function and oxidative stress in a head-to-head trial. Methods: Thirty-four patients with type 2 diabetes mellitus (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or metoprolol (n = 18) in addition to their current antihypertensive medications for 5 months. The following variables were measured pre- and posttreatment: blood pressure, fasting glucose and insulin, insulin resistance by homeostasis-model assessment, hemoglobin A1c, lipids, C-reactive protein (CRP), 8-isoprostane, asymmetric dimethylarginine, oxidized LDL cholesterol, ultrasound assessment of brachial-artery flow-mediated dilation (FMD), nitroglycerin-induced endothelium-independent dilation (EID), brachial and carotid artery distension, distensibility and compliance, and carotid artery intima-media thickness (cIMT). Results: Both carvedilol and metoprolol treatment resulted in significant and similar decreases in systolic (P < .05) and diastolic (P < .0001) blood pressure. Compared with metoprolol, carvedilol significantly improved FMD (P < .001). No differences between groups were noted for any of the glycemic or lipid variables except for HDL cholesterol, which significantly decreased (P < .05) in the metoprolol group compared with the carvedilol group. No differences were observed between groups for CRP, the markers of oxidative stress, EID, arterial stiffness, or cIMT. Conclusions: Compared with metoprolol, carvedilol significantly improves endothelial function in patients with T2DM. Changes in glycemic control and oxidative stress do not seem to explain the observed improvements in FMD, which suggests that other mechanisms may be involved.

KW - endothelial function

KW - oxidative stress

KW - type 2 diabetes mellitus

KW - β-blocker

UR - http://www.scopus.com/inward/record.url?scp=34250638587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250638587&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2007.01.019

DO - 10.1016/j.amjhyper.2007.01.019

M3 - Article

C2 - 17586413

AN - SCOPUS:34250638587

VL - 20

SP - 777

EP - 783

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 7

ER -